ADVANCE
2008
Action in Diabetes and Vascular Disease
In 11,140 patients with T2DM at high CV risk, gliclazide-based intensive control to HbA1c ≤6.5 % reduced the composite of microvascular and macrovascular events versus standard care.
Result
Efficacy: Composite microvascular + macrovascularHR 0.90 (CI 0.82-0.98) · P = 0.01
Below 1 favours gliclazide-based intensive control to HbA1c ≤6.5 %, above 1 favours standard care.
Also reported: Driven by −21 % new/worsening nephropathy. No mortality increase, no macrovascular benefit.
- Subtopic
- Intensive vs standard glycaemia
- Design
- RCT, median 5 yr
- Relevance
- Important: one of several pillars.
- Source
- ADVANCE Collaborative Group. N Engl J Med. 2008;358(24):2560-2572.doi 10.1056/NEJMoa0802987
Discussion & critique
Counterweight to ACCORD: intensive control with gliclazide was safe, modestly renoprotective and free of the ACCORD mortality signal.